Pathogenesis of lymphatic disease in bancroftian filariasis: a clinical perspective.
The pathogenesis of lymphatic filariasis has been a matter of debate for many decades. Here, Gerusa Dreyer and colleagues propose a dynamic model of bancroftian filariasis, integrating clinical, parasitological, surgical, therapeutic, ultrasonographic and histopathological data. This model has profound implications for filariasis control programs and the management of the individual patient.
Dreyer
G
G
NEPAF, Departamento de Cirurgia Hospital das Clinicas, Universidade Federal de Pernambuco, Av. Prof Moraes Rego, s/n 5o andar, Cidade Universitária, Recife, 50740-900, PE, Brazil. gd@nlink.com.br
Norões
J
J
Figueredo-Silva
J
J
Piessens
W F
WF
D015766:Albendazole / Q000627:therapeutic use; D000818:Animals; D000871:Anthelmintics / Q000627:therapeutic use; D004049:Diethylcarbamazine / Q000627:therapeutic use; D004605:Elephantiasis, Filarial / Q000188:drug therapy / Q000209:etiology* / Q000517:prevention & control / Q000601:surgery; D005260:Female; D005369:Filaricides / Q000627:therapeutic use; D006801:Humans; D007559:Ivermectin / Q000627:therapeutic use; D008205:Lymphangitis / Q000188:drug therapy / Q000473:pathology; D008297:Male; D008954:Models, Biological; D012611:Scrotum / Q000473:pathology; D006848:Testicular Hydrocele / Q000601:surgery; D014958:Wuchereria bancrofti / Q000472:pathogenicity*
D000871:Anthelmintics; D005369:Filaricides; D007559:Ivermectin; D015766:Albendazole; D004049:Diethylcarbamazine